Therapeutic Maintenance of Baricitinib and Tofacitinib in Real Life.
Valentine DeprezLaure Le MonnierJean-Marc Sobhy-DanialFranck GradosIsabelle Henry-DesaillySarah Salomon-GoëbThibault RabinSanja RisticMathurin FumeryPatrice FardelloneVincent GoebPublished in: Journal of clinical medicine (2020)
Our study found that a higher Charlson index, age, and corticosteroids appeared to be associated with the earlier discontinuation of treatment. JAKis had a response and tolerance profile in real life at least equivalent to that of biological disease-modifying antirheumatic drugs (bDMARDs).